鲜红斑痣发病及进展机制研究进展

doi:10.35541/cjd.20240052

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (7): 661-664.doi: 10.35541/cjd.20240052

鲜红斑痣发病及进展机制研究进展

陈浩天刘莲张婷刘青锋李晓雪刁萍蒋献

四川大学华西医院皮肤性病科四川大学疾病分子网络前沿科学中心免疫炎症研究院皮肤病学研究室，成都 610041

收稿日期:2024-01-26 修回日期:2024-04-23 发布日期:2024-07-02
通讯作者: 蒋献 E-mail:jiangxian@scu.edu.cn
基金资助:
国家自然科学基金（82003373）；四川大学华西医院学科卓越发展1.3.5工程项目（ZYJC21036）

Port-wine stains: mechanisms underlying the development and progression

Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian

Department of Dermatology and Venereology, West China Hospital, Sichuan University; Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, Sichuan University, Chengdu 610041, China

Received:2024-01-26 Revised:2024-04-23 Published:2024-07-02
Contact: Jiang Xian E-mail:jiangxian@scu.edu.cn
Supported by:
National Natural Science Foundation of China （82003373）; 1.3.5 Project of Discipline Excellence Development of West China Hospital of Sichuan University （ZYJC21036）

摘要/Abstract

摘要： 【摘要】鲜红斑痣是一种主要累及皮肤的毛细血管和毛细血管后微静脉的血管疾病。临床主要表现为粉色或红色不规则斑片，大部分皮损随患者年龄增长可出现增厚、颜色加深，甚至出现结节，治疗难度进一步增加。鲜红斑痣的发病及进展机制尚不十分清楚，可能与遗传因素、基因突变、血管神经比例异常等相关，本文综述鲜红斑痣发病及进展的机制。

关键词: 葡萄酒色痣, 血管畸形, 治疗, 发病机制, 疾病进展

Abstract: 【Abstract】 Port-wine stains （PWS） are vascular malformations characterized by dilated capillaries and postcapillary venules in the skin. Clinically, they mainly manifest as pink or red irregular patches, most of which may become thickened, darkened in color, or even develop into nodules over age, making treatment more challenging. The mechanisms underlying the development and progression of PWS are not very clear, and may be related to heredity, gene mutations, abnormal ratios of blood vessels to nerves, etc. This review summarizes research progress in the mechanisms underlying the development and progression of PWS, so as to provide a theoretical basis for their treatment.

Key words: Port-wine stain, Vascular malformations, Therapy, Pathogenesis, Disease progression

陈浩天刘莲张婷刘青锋李晓雪刁萍蒋献. 鲜红斑痣发病及进展机制研究进展[J]. 中华皮肤科杂志, 2024,57(7):661-664. doi:10.35541/cjd.20240052

Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression[J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664.doi:10.35541/cjd.20240052

参考文献 43

［1］	Escobar K, Pandher K, Jahnke MN. Capillary malformations［J］. Dermatol Clin, 2022,40（4）:425⁃433. doi: 10.1016/j.det.2022. 06.005.
［2］	刘莲, 张自晖, 郝丹, 等. 鲜红斑痣的发病机制研究进展［J］. 中国麻风皮肤病杂志, 2019,35（4）:253⁃256.
［3］	Brightman LA, Geronemus RG, Reddy KK. Laser treatment of port⁃wine stains［J］. Clin Cosmet Investig Dermatol, 2015,8:27⁃33. doi: 10.2147/CCID.S53118.
［4］	Orten SS, Waner M, Flock S, et al. Port⁃wine stains. An assessment of 5 years of treatment［J］. Arch Otolaryngol Head Neck Surg, 1996,122（11）:1174⁃1179. doi: 10.1001/archotol. 1996.01890230022005.
［5］	Michel S, Landthaler M, Hohenleutner U. Recurrence of port⁃wine stains after treatment with the flashlamp⁃pumped pulsed dye laser［J］. Br J Dermatol, 2000,143（6）:1230⁃1234. doi: 10. 1046/j.1365⁃2133.2000.03893.x.
［6］	Kang J, Liu JJ, Fang YH, et al. Hemoporfin⁃mediated photodynamic therapy for port⁃wine stains on extremities［J］. Dermatol Ther （Heidelb）, 2023,13（8）:1857⁃1871. doi: 10.1007/s13555⁃023⁃00970⁃8.
［7］	Sun J, Zhang Y, Ma T, et al. Efficacy of hemoporfin⁃PDT on port⁃wine stains: a retrospective analysis of 2952 cases［J］. Photodiagnosis Photodyn Ther, 2023,44:103837. doi: 10.1016/j.pdpdt.2023.103837.
［8］	Peng X, Ye T, Yu B, et al. Comparing HMME⁃PDT and Cynergy dual⁃wavelength laser in the treatment of facial PWS［J］. Photodiagnosis Photodyn Ther, 2022,37:102703. doi: 10.1016/j.pdpdt.2021.102703.
［9］	Kunimoto K, Yamamoto Y, Jinnin M. ISSVA classification of vascular anomalies and molecular biology［J］. Int J Mol Sci, 2022,23（4）:2358. doi: 10.3390/ijms23042358.
［10］	阚云珍, 缑向楠, 赵跃武, 等. 葡萄酒色斑和Sturge⁃Weber综合征的临床病理及分子遗传学特征［J］. 中华病理学杂志, 2021,50（7）: 802⁃804. doi: 10.3760cma.j.cn112151⁃20210425⁃00316.
［11］	Xu MN, Wang Q, Wang M, et al. Enhanced activation of mTOR signaling pathway was found in the hypertrophic and nodular lesions of port wine stains［J］. Clin Cosmet Investig Dermatol, 2022,15:643⁃651. doi: 10.2147/CCID.S358612.
［12］	李勤, 彭丽霞, 苑凯华, 等. 光动力疗法对鲜红斑痣血管组织学的影响探讨［J］. 广东医学, 2010,31（7）:852⁃854. doi: 10. 3969/j.issn.1001⁃9448.2010.07.020.
［13］	Liu L, Zhou L, Zhao Q, et al. Histological analysis of different types of port⁃wine stains to guide clinical decision making: a retrospective study［J］. Indian J Dermatol Venereol Leprol, 2023,89（2）:204⁃212. doi: 10.25259/IJDVL_730_2021.
［14］	Fölster⁃Holst R, Shukla R, Kassir M, et al. Treatment update of port⁃wine stain: a narrative review［J］. J Drugs Dermatol, 2021,20（5）:515⁃518. doi: 10.36849/JDD.5005.
［15］	Tan W, Zakka LR, Gao L, et al. Pathological alterations involve the entire skin physiological milieu in infantile and early⁃childhood port⁃wine stain［J］. Br J Dermatol, 2017,177（1）:293⁃296. doi: 10.1111/bjd.15068.
［16］	Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port⁃wine stains［J］. J Dermatol Surg Oncol, 1991,17（1）:76⁃79. doi: 10.1111/j.1524⁃4725.1991.tb01597.x.
［17］	Chen D, Hu XJ, Lin XX, et al. Nodules arising within port⁃wine stains: a clinicopathologic study of 31 cases［J］. Am J Dermatopathol, 2011,33（2）:144⁃151. doi: 10.1097/DAD.0b013e3181e169f5.
［18］	Gao L, Yin R, Wang H, et al. Ultrastructural characterization of hyperactive endothelial cells, pericytes and fibroblasts in hypertrophic and nodular port⁃wine stain lesions［J］. Br J Dermatol, 2017,177（4）:e105⁃e108. doi: 10.1111/bjd.15373.
［19］	Burrows PE. Angioarchitecture of hereditary arteriovenous malformations［J］. Semin Intervent Radiol, 2017,34（3）:250⁃257. doi: 10.1055/s⁃0037⁃1604298.
［20］	Delagrange L, Dupuis O, Fargeton AE, et al. Obstetrical and neonatal complications in hereditary haemorrhagic telangiectasia: a retrospective study［J］. BJOG, 2023,130（3）:303⁃311. doi: 10. 1111/1471⁃0528.17303.
［21］	Eerola I, Boon LM, Watanabe S, et al. Locus for susceptibility for familial capillary malformation （'port⁃wine stain'） maps to 5q［J］. Eur J Hum Genet, 2002,10（6）:375⁃380. doi: 10.1038/sj.ejhg.5200817.
［22］	Troilius Rubin A, Lauritzen E, Ljunggren B, et al. Heredity of port⁃wine stains: investigation of families without a RASA1 mutation［J］. J Cosmet Laser Ther, 2015,17（4）:204⁃208. doi: 10.3109/14764172.2015.1007060.
［23］	Shirley MD, Tang H, Gallione CJ, et al. Sturge⁃Weber syndrome and port⁃wine stains caused by somatic mutation in GNAQ［J］. N Engl J Med, 2013,368（21）:1971⁃1979. doi: 10.1056/NEJMoa 1213507.
［24］	Lee KT, Park JE, Eom Y, et al. Phenotypic association of presence of a somatic GNAQ mutation with port⁃wine stain distribution in capillary malformation［J］. Head Neck, 2019,41（12）:4143⁃4150. doi: 10.1002/hed.25962.
［25］	Lian CG, Sholl LM, Zakka LR, et al. Novel genetic mutations in a sporadic port⁃wine stain［J］. JAMA Dermatol, 2014,150（12）:1336⁃1340. doi: 10.1001/jamadermatol.2014.1244.
［26］	Huang L, Bichsel C, Norris AL, et al. Endothelial GNAQ p.R183Q increases ANGPT2 （Angiopoietin⁃2） and drives formation of enlarged blood vessels［J］. Arterioscler Thromb Vasc Biol, 2022,42（1）:e27⁃e43. doi: 10.1161/ATVBAHA.121.316651.
［27］	Öztürk Durmaz E, Demircioğlu D, Yalınay Dikmen P, et al. A review on cutaneous and musculoskeletal manifestations of CLOVES syndrome［J］. Clin Cosmet Investig Dermatol, 2022,15:621⁃630. doi: 10.2147/CCID.S351637.
［28］	Canaud G, Hammill AM, Adams D, et al. A review of mechanisms of disease across PIK3CA⁃related disorders with vascular manifestations［J］. Orphanet J Rare Dis, 2021,16（1）:306. doi: 10.1186/s13023⁃021⁃01929⁃8.
［29］	Chen K, Hu YY, Wang LL, et al. Whole⁃genome sequencing identified KCNJ12 and SLC25A5 mutations in port⁃wine stains［J］. Front Med （Lausanne）, 2022,9:905902. doi: 10.3389/fmed. 2022.905902.
［30］	Baqai U, Kurimchak AM, Trachtenberg IV, et al. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma［J］. J Biol Chem, 2023,299（12）:105418. doi: 10.1016/j.jbc.2023.105418.
［31］	Yue J, López JM. Understanding MAPK signaling pathways in apoptosis［J］. Int J Mol Sci, 2020,21（7）:2346. doi: 10.3390/ijms 21072346.
［32］	Tursch A, Holstein TW. From injury to patterning⁃MAPKs and Wnt signaling in Hydra［J］. Curr Top Dev Biol, 2023,153:381⁃417. doi: 10.1016/bs.ctdb.2023.01.003.
［33］	Bonni A, Brunet A, West AE, et al. Cell survival promoted by the Ras⁃MAPK signaling pathway by transcription⁃dependent and ⁃independent mechanisms［J］. Science, 1999,286（5443）:1358⁃1362. doi: 10.1126/science.286.5443.1358.
［34］	迪丽努尔·吾甫尔, 丁媛, 康晓静. 鲜红斑痣相关基因及激酶的研究进展［J］. 医学综述, 2022,28（6）:1085⁃1090. doi: 10. 3969/j.issn.1006⁃2084.2022.06.009.
［35］	Vindis C, Cerretti DP, Daniel TO, et al. EphB1 recruits c⁃Src and p52Shc to activate MAPK/ERK and promote chemotaxis［J］. J Cell Biol, 2003,162（4）:661⁃671. doi: 10.1083/jcb.200302073.
［36］	Zhao Y, Dong J, Liao Y, et al. Identification and validation of four photodynamic therapy related genes inhibiting MAPK and inducing cell cycle alteration in squamous cell carcinoma［J］. Front Oncol, 2022,12:946493. doi: 10.3389/fonc.2022.946493.
［37］	Garcia⁃Lezana T, Lopez⁃Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma［J］. Adv Cancer Res, 2021,149:63⁃101. doi: 10.1016/bs.acr.2020.10.002.
［38］	Tan W, Chernova M, Gao L, et al. Sustained activation of c⁃Jun N⁃terminal and extracellular signal⁃regulated kinases in port⁃wine stain blood vessels［J］. J Am Acad Dermatol, 2014,71（5）:964⁃968. doi: 10.1016/j.jaad.2014.07.025.
［39］	Yin R, Gao L, Tan W, et al. Activation of PKCα and PI3K kinases in hypertrophic and nodular port wine stain lesions［J］. Am J Dermatopathol, 2017,39（10）:747⁃752. doi: 10.1097/DAD. 0000000000000785.
［40］	Smoller BR, Rosen S. Port⁃wine stains. A disease of altered neural modulation of blood vessels?［J］. Arch Dermatol, 1986,122（2）:177⁃179. doi: 10.1001/archderm.122.2.177.
［41］	Poliner A, Fernandez Faith E, Blieden L, et al. Port⁃wine birthmarks: update on diagnosis, risk assessment for Sturge⁃Weber syndrome, and management［J］. Pediatr Rev, 2022,43（9）:507⁃516. doi: 10.1542/pir.2021⁃005437.
［42］	Finley JL, Noe JM, Arndt KA, et al. Port⁃wine stains. Morphologic variations and developmental lesions［J］. Arch Dermatol, 1984,120（11）:1453⁃1455. doi: 10.1001/archderm.120. 11.1453.
［43］	Rydh M, Malm M, Jernbeck J, et al. Ectatic blood vessels in port⁃wine stains lack innervation: possible role in pathogenesis［J］. Plast Reconstr Surg, 1991,87（3）:419⁃422. doi: 10.1097/00006534⁃ 199103000⁃00003.

[1]	刘青锋刘莲刁萍李晓雪张婷陈浩天刘绪蒋献. 鲜红斑痣相关综合征的诊疗进展[J]. 中华皮肤科杂志, 2024, 57(7): 656-660.
[2]	刁萍韩成龙刘莲周慧李二龙蒋献. 海姆泊芬光动力治疗成人鲜红斑痣的疗效及其影响因素分析：一项回顾性研究[J]. 中华皮肤科杂志, 2024, 57(7): 595-600.
[3]	张婷刘莲陈浩天魏丹凤刘绪刁萍刘青锋蒋献. 595 nm脉冲染料激光治疗155例婴幼儿鲜红斑痣疗效回顾性分析[J]. 中华皮肤科杂志, 2024, 57(7): 610-615.
[4]	张升王秀伟陈见友邓维张海花张高磊刘晓雁苏伟. 海姆泊芬光动力疗法对15例Sturge-Weber综合征患儿面部鲜红斑痣的疗效观察[J]. 中华皮肤科杂志, 2024, 57(7): 616-622.
[5]	蒋献刘莲张婷. 鲜红斑痣的治疗现状及展望[J]. 中华皮肤科杂志, 2024, 57(7): 590-594.
[6]	海姆泊芬光动力疗法治疗鲜红斑痣共识制订专家组. [开放获取] 海姆泊芬光动力疗法治疗鲜红斑痣专家共识（2024）[J]. 中华皮肤科杂志, 2024, 57(7): 581-589.
[7]	王林霞张立明史美慧高兴华陈洪铎肖汀. 慢性自发性荨麻疹伴与不伴血管性水肿患者131例临床特征回顾分析[J]. 中华皮肤科杂志, 2024, 57(6): 510-515.
[8]	中华医学会医学美学与美容学分会激光美容学组中国医学装备协会皮肤病与皮肤美容分会护肤品和护肤材料学组中国医师协会整形与美容分会激光美容学组中华医学会皮肤性病学分会美容激光学组 . [开放获取] 化妆品皮肤不良反应诊疗指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(6): 485-492.
[9]	封梦荻王文氢. 转录因子和受体调控痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 575-578.
[10]	隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574.
[11]	王晨薛晨红宋静卉李建国李振鲁张守民李明王建波. 阿达木单抗治疗Blau综合征1家系3例[J]. 中华皮肤科杂志, 2024, 57(6): 553-556.
[12]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[13]	中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 387-399.
[14]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[15]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.

鲜红斑痣发病及进展机制研究进展

Port-wine stains: mechanisms underlying the development and progression

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

Metrics

本文评价

推荐阅读 10